Clinical Trial Update: Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. [Phase 1, Phase 2]

View source ↗

Summary

An update on a Phase 1/2 trial evaluating the combination of alpelisib and tucatinib in patients with PIK3CA-mutant, HER2-positive metastatic breast cancer. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Alpelisib (alpelisib)
• Tucatinib (tucatinib)

Snippet

Sponsor: Criterium, Inc. | Conditions: HER2-positive Metastatic Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING